An advanced understanding of the pathogenesis of psoriasis has led to the development of
multiple therapeutic options for moderate-to-severe psoriasis. Tumor necrosis factor …

The emergence of data from clinical trials of biologics, the approval of new biologics, and
our improved understanding of psoriasis pathogenesis have increased the therapeutic …

Psoriasis is a systemic immune-mediated disease associated with an increased risk of
comorbidities, such as psoriatic arthritis, cardiovascular disease, metabolic syndrome …

Abstract Ustekinumab is an interleukin-12/23 inhibitor used for the treatment of moderate-to-
severe psoriasis. Here, we review new evidence since ustekinumab was licensed for …

Purpose Advances in the treatment of moderate-to-severe plaque psoriasis, including new
biological agents and related drugs, are reviewed. Summary Most patients with psoriasis …

Therapy of Moderate-to-Severe-Psoriasis Page 1 El- :* Y ||||| Therapy of Moderate-to-Severe
Psoriasis Second Edition, Revised and Expanded edited by Gerald D. Weinstein Alice B …

The development of targeted biologic agents has revolutionized the treatment of psoriasis. In
this review, the authors focus on the published long-term (≥ one year) safety data for the …

Background The treatment of psoriasis has evolved over the years, with the focus now
largely on the use of biologic agents. With treatment options expanding, evidence-based …

Background. The role of interleukin‐12 (IL‐12), interleukin‐23 (IL‐23), and interleukin‐17 (IL‐
17) has been recognized in psoriasis pathogenesis, and new drugs targeting this axis have …

Psoriasis is an immune-mediated polygenic inherited skin disease. Many biologic agents
have been approved for the treatment of moderate-to-severe plaque psoriasis. The most …